Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionBellevue Group AG
Latest Disclosed Ownership234,543 shares
Latest Disclosed Value $ 77,603,243
Bellevue Group AG reports 47.40% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Bellevue Group AG filed a 13F-HR form disclosing ownership of 234,543 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $67,008,935 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 445,903 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -47.40% during the quarter. The current value of the position is $59,057,927 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 234,543 -211,360 -47.40 77,603 -56.23 1.8342
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 445,903 -621 -0.14 177,313 -12.92 3.3602
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 446,524 -229,843 -33.98 203,615 -7.68 4.2307
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 676,367 -91,780 -11.95 220,557 6.34 4.8611
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 768,147 -2,121 -0.28 207,415 14.44 4.6476
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 770,268 -38,827 -4.80 181,252 -18.55 3.4889
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 809,095 -110,739 -12.04 222,525 -0.44 3.6050
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 919,834 1,550 0.17 223,520 62.87 3.6319
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 918,284 32,966 3.72 137,238 -19.01 2.0930
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 885,318 -9,027 -1.01 169,459 6.99 2.5921
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 894,345 -5,305 -0.59 158,388 -7.31 2.5518
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 899,650 16,400 1.86 170,880 -3.42 2.4375
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 883,250 -37,963 -4.12 176,933 -19.18 2.5675
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 921,213 -35,549 -3.72 218,926 14.32 2.9056
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 956,762 -101,424 -9.58 191,505 24.08 2.7485
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,058,186 -171,377 -13.94 154,336 -23.13 2.1817
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,229,563 -105,577 -7.91 200,776 -11.32 2.3314
2022-02-10 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,335,140 -73,278 -5.20 226,413 -14.86 2.3338
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,408,418 -140,674 -9.08 265,924 1.27 2.6986
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,549,092 -78,022 -4.80 262,602 14.31 2.5634
2021-05-12 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,627,114 23,614 1.47 229,733 10.23 2.4306
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,603,500 43,695 2.80 208,406 -8.23 2.3867
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,559,805 -50,260 -3.12 227,108 -4.76 3.1380
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,610,065 -165,199 -9.31 238,467 23.41 3.3749
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,775,264 -89,519 -4.80 193,237 -10.02 3.7474
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,864,783 -100,289 -5.10 214,767 35.90 3.4050
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,965,072 37,678 1.95 158,031 13.00 2.9391
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,927,394 1,660,089 621.05 139,852 459.86 2.3879
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 267,305 42,920 19.13 24,980 52.69 1.3745
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 224,385 4,494 2.04 16,360 -14.99 1.0756
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 219,891 116,391 112.46 19,245 88.79 1.2208
2018-08-07 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 103,500 81,750 375.86 10,194 293.59 0.8691
2018-05-09 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,750 -350 -1.58 2,590 -7.76 0.2566
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,100 -53,493 -70.76 2,808 -68.37 0.2933
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 75,593 -49,436 -39.54 8,878 -10.97 0.9285
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 125,029 -16,871 -11.89 9,972 37.13 1.1791
2017-05-11 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 141,900 117,900 491.25 7,272 708.90 0.9691
2017-02-10 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,000 0 0.00 899 -44.74 0.1841
2016-11-10 2016-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 24,000 0 0.00 1,627 22.15 0.2939
2016-08-12 2016-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 24,000 0 0.00 1,332 -11.55 0.2506
2016-05-16 2016-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 24,000 24,000 1,506 0.2733
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.